Elevance Health Q4 EPS falls to $1.81 from $3.63; revenue rises 6% to $45.0 billion
Elevance Health reported fourth quarter 2024 operating revenue of $45.0 billion, up 6% from a year earlier, but diluted EPS fell to $1.81 from $3.63 and adjusted diluted EPS fell to $3.84 from $5.62. The company also projected 2025 adjusted diluted EPS of $34.15 to $34.85 and raised its quarterly dividend 5% to $1.71 per share, which matters to shareholders because it shows the company's near-term earnings outlook and cash returns.
Key points
- Q4 2024 operating revenue was $45.0 billion, up 6%; benefit expense ratio rose to 92.4% from 89.2%, driven mainly by higher Medicaid medical cost trends.
- Full year 2024 diluted EPS was $25.68, up 1.8%; adjusted diluted EPS was $33.04, down 0.3%.
- Projected 2025 GAAP diluted EPS is $30.40 to $31.10 and adjusted diluted EPS is $34.15 to $34.85.
- The first quarter 2025 dividend is $1.71 per share, payable March 25, 2025, up 5% from $1.63.
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 23, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.